{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:56:41Z","timestamp":1782388601782,"version":"3.54.5"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To investigate the 1-year risks of Staphylococcus aureus bacteraemia (SAB), sepsis, and pneumonia in patients who underwent percutaneous coronary intervention and were treated with ticagrelor vs. clopidogrel.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>In this nationwide observational cohort study, 26\u00a0606 patients who underwent urgent or emergent percutaneous coronary intervention (January 2011\u2013December 2017) and initiated treatment with ticagrelor [N\u2009=\u200920\u00a0073 (75.5%); median age 64\u2009years (25th\u201375th percentile 55\u201372\u2009years); 74.8% men] or clopidogrel [N\u2009=\u20096533 (24.5%); median age 68\u2009years (25th\u201375th percentile 58\u201377\u2009years); 70.2% men] were identified using Danish nationwide registries. The 1-year standardized absolute risks of outcomes was calculated based on cause-specific Cox regression models, and average treatment effects between treatment groups were obtained as standardized differences in absolute 1-year risks. The absolute 1-year risk of SAB was 0.10% [95% confidence interval (CI), 0.05\u20130.15%] in the ticagrelor group and 0.29% (95% CI, 0.17\u20130.42%) in the clopidogrel group. Compared with clopidogrel, treatment with ticagrelor was associated with a significantly lower absolute 1-year risk of SAB [absolute risk difference \u22120.19% (95% CI, \u22120.32% to \u22120.05%), P value 0.006]. Likewise, treatment with ticagrelor was associated with a significantly lower absolute 1-year risk of sepsis [0.99% (95% CI, 0.83\u20131.14%) vs. 1.49% (95% CI, 1.17\u20131.80%); absolute risk difference \u22120.50% (95% CI, \u22120.86% to \u22120.14%), P value 0.007] and pneumonia [3.13% (95% CI, 2.86\u20133.39%) vs. 4.56% (95% CI, 4.03\u20135.08%); absolute risk difference \u22121.43% (95% CI, \u22122.03% to \u22120.82%), P value &amp;lt; 0.001] compared with clopidogrel.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Treatment with ticagrelor was associated with a significantly lower 1-year risk of SAB, sepsis, and pneumonia compared with clopidogrel.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaa099","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T11:28:31Z","timestamp":1596194911000},"page":"13-19","source":"Crossref","is-referenced-by-count":18,"title":["Ticagrelor and the risk of <i>Staphylococcus aureus<\/i> bacteraemia and other infections"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-4144","authenticated-orcid":false,"given":"Jawad H","family":"Butt","sequence":"first","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil L","family":"Fosb\u00f8l","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Gerds","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark"},{"name":"The Danish Heart Foundation, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper","family":"Iversen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev and Gentofte University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Bundgaard","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Eske","family":"Bruun","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zealand University Hospital, Roskilde, Denmark"},{"name":"Institute of Clinical Medicine, Copenhagen University, Copenhagen, Denmark"},{"name":"Clinical Institute, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders R","family":"Larsen","sequence":"additional","affiliation":[{"name":"Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Petersen","sequence":"additional","affiliation":[{"name":"Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paal S","family":"Andersen","sequence":"additional","affiliation":[{"name":"Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6079-5381","authenticated-orcid":false,"given":"Robert L","family":"Skov","sequence":"additional","affiliation":[{"name":"Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauge","family":"\u00d8stergaard","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Havers-Borgersen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-402X","authenticated-orcid":false,"given":"Gunnar H","family":"Gislason","sequence":"additional","affiliation":[{"name":"The Danish Heart Foundation, Copenhagen, Denmark"},{"name":"Department of Cardiology, Herlev and Gentofte University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Torp-Pedersen","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Clinical Investigation, Nordsj\u00e6llands Hospital, Hiller\u00f8d, Denmark"},{"name":"Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas B","family":"Olesen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev and Gentofte University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"key":"2022030710590907400_pvaa099-B1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2022030710590907400_pvaa099-B2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"2022030710590907400_pvaa099-B3","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022030710590907400_pvaa099-B4","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1161\/ATVBAHA.111.226845","article-title":"Regulation of neutrophil function by adenosine","volume":"32","author":"Barletta","year":"2012","journal-title":"Arter Thromb Vasc Biol"},{"key":"2022030710590907400_pvaa099-B5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/ATVBAHA.111.226852","article-title":"Regulation of macrophage function by adenosine","volume":"32","author":"Hasko","year":"2012","journal-title":"Arter Thromb Vasc Biol"},{"key":"2022030710590907400_pvaa099-B6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.vph.2015.02.006","article-title":"Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosis","volume":"71","author":"Alsharif","year":"2015","journal-title":"Vasc Pharmacol"},{"key":"2022030710590907400_pvaa099-B7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jacbts.2018.05.005","article-title":"Ticagrelor reduces thromboinflammatory markers in patients with pneumonia","volume":"3","author":"Sexton","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"2022030710590907400_pvaa099-B8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3109\/09537104.2013.842965","article-title":"Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study","volume":"25","author":"Storey","year":"2014","journal-title":"Platelets"},{"key":"2022030710590907400_pvaa099-B9","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamacardio.2019.1189","article-title":"Antibacterial activity of ticagrelor in conventional antiplatelet dosages against antibiotic-resistant gram-positive bacteria","volume":"4","author":"Lancellotti","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2022030710590907400_pvaa099-B10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"key":"2022030710590907400_pvaa099-B11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish National Prescription Registry","volume":"39","author":"Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"key":"2022030710590907400_pvaa099-B12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish Civil Registration System","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J Public Health"},{"key":"2022030710590907400_pvaa099-B13","author":"Borck","year":"2017"},{"key":"2022030710590907400_pvaa099-B14","article-title":"Staphylococcus aureus bacteraemia cases in Denmark","volume-title":"Statens Serum Institut","author":"Petersen","year":"2017"},{"key":"2022030710590907400_pvaa099-B15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1403494811405098","article-title":"Danish registers on personal income and transfer payments","volume":"39","author":"Baadsgaard","year":"2011","journal-title":"Scand J Public Health"},{"key":"2022030710590907400_pvaa099-B16","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.107.720847","article-title":"Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people","volume":"117","author":"Schramm","year":"2008","journal-title":"Circulation"},{"key":"2022030710590907400_pvaa099-B17","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"key":"2022030710590907400_pvaa099-B18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2307\/2532098","article-title":"Estimates of absolute cause-specific risk in cohort studies","volume":"46","author":"Benichou","year":"1990","journal-title":"Biometrics"},{"key":"2022030710590907400_pvaa099-B19","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/01.EDE.0000081989.82616.7d","article-title":"Marginal structural models as a tool for standardization","volume":"14","author":"Sato","year":"2003","journal-title":"Epidemiology"},{"key":"2022030710590907400_pvaa099-B20","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2019"},{"key":"2022030710590907400_pvaa099-B21","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.114.014335","article-title":"Coronary artery bypass grafting in patients 50 years or younger: a Swedish nationwide cohort study","volume":"131","author":"Dalen","year":"2015","journal-title":"Circulation"},{"key":"2022030710590907400_pvaa099-B22","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1055\/s-0037-1613242","article-title":"Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin","volume":"88","author":"Storey","year":"2002","journal-title":"Thromb Haemost"},{"key":"2022030710590907400_pvaa099-B23","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1046\/j.1365-2141.2000.02208.x","article-title":"The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity","volume":"110","author":"Storey","year":"2000","journal-title":"Br J Haematol"},{"key":"2022030710590907400_pvaa099-B24","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022030710590907400_pvaa099-B25","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1160\/TH14-12-1068","article-title":"Effect of P2Y12 inhibitors on inflammation and immunity","volume":"114","author":"Thomas","year":"2015","journal-title":"Thromb Haemost"},{"key":"2022030710590907400_pvaa099-B26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1074248413511693","article-title":"Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1","volume":"19","author":"Armstrong","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2022030710590907400_pvaa099-B27","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2013.09.067","article-title":"Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome","volume":"63","author":"Bonello","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022030710590907400_pvaa099-B28","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1182\/blood-2016-03-707844","article-title":"Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor","volume":"128","author":"Aungraheeta","year":"2016","journal-title":"Blood"},{"key":"2022030710590907400_pvaa099-B29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3201\/eid2505.181733","article-title":"Age-dependent increase in incidence of Staphylococcus aureus bacteremia, Denmark, 2008\u20132015","volume":"25","author":"Thorlacius-Ussing","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2022030710590907400_pvaa099-B30","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.jacc.2019.03.470","article-title":"Premature ticagrelor discontinuation in secondary prevention of atherosclerotic CVD: JACC review topic of the week","volume":"73","author":"Arora","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaa099\/33771471\/pvaa099.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/1\/13\/42750597\/pvaa099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/1\/13\/42750597\/pvaa099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T10:59:47Z","timestamp":1646650787000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/8\/1\/13\/5880551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,4]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,8,4]]},"published-print":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa099","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1]]},"published":{"date-parts":[[2020,8,4]]}}}